Bank of Montreal Can bought a new stake in shares of CME Group Inc. (NASDAQ:CME) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 365,953 shares of the company’s stock, valued at approximately $35,643,000.
A number of other institutional investors have also bought and sold shares of the stock. Legal & General Group Plc raised its position in CME Group by 2.0% in the first quarter. Legal & General Group Plc now owns 1,391,482 shares of the company’s stock valued at $133,643,000 after buying an additional 27,322 shares during the period. AMP Capital Investors Ltd raised its position in CME Group by 10.6% in the first quarter. AMP Capital Investors Ltd now owns 278,973 shares of the company’s stock valued at $26,661,000 after buying an additional 26,751 shares during the period. Franklin Resources Inc. acquired a new position in CME Group during the first quarter valued at approximately $222,000. Gofen & Glossberg LLC IL raised its position in CME Group by 0.4% in the second quarter. Gofen & Glossberg LLC IL now owns 7,323 shares of the company’s stock valued at $713,000 after buying an additional 26 shares during the period. Finally, Capstone Asset Management Co. raised its position in CME Group by 10.2% in the first quarter. Capstone Asset Management Co. now owns 27,962 shares of the company’s stock valued at $2,686,000 after buying an additional 2,580 shares during the period. 80.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CME Group Inc. (NASDAQ:CME) traded down 1.78% on Friday, reaching $106.49. 1,787,501 shares of the company’s stock were exchanged. The company has a market capitalization of $36.08 billion, a P/E ratio of 26.89 and a beta of 0.85. CME Group Inc. has a 1-year low of $81.87 and a 1-year high of $110.35. The stock’s 50-day moving average price is $106.63 and its 200-day moving average price is $98.75.
CME Group (NASDAQ:CME) last released its earnings results on Thursday, July 28th. The company reported $1.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.03. The company earned $906 million during the quarter, compared to the consensus estimate of $897.84 million. CME Group had a net margin of 38.22% and a return on equity of 6.83%. The company’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.95 EPS. Analysts anticipate that CME Group Inc. will post $4.44 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, September 26th. Stockholders of record on Friday, September 9th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 2.25%. The ex-dividend date is Wednesday, September 7th. CME Group’s payout ratio is currently 60.61%.
Several equities analysts recently commented on CME shares. Jefferies Group increased their target price on CME Group from $112.00 to $118.00 and gave the company a “buy” rating in a report on Wednesday, August 31st. JPMorgan Chase & Co. set a $116.00 price objective on shares of CME Group and gave the company a “buy” rating in a research note on Monday, September 12th. Zacks Investment Research upgraded shares of CME Group from a “sell” rating to a “hold” rating in a research note on Thursday, June 30th. Credit Suisse Group AG decreased their price objective on shares of CME Group from $100.00 to $94.00 and set a “neutral” rating for the company in a research note on Wednesday, June 1st. Finally, Deutsche Bank AG upped their price objective on shares of CME Group from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $102.89.
In other news, CEO Phupinder Gill sold 30,002 shares of CME Group stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $110.00, for a total value of $3,300,220.00. Following the completion of the transaction, the chief executive officer now directly owns 116,222 shares of the company’s stock, valued at approximately $12,784,420. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Martin J. Gepsman sold 300 shares of CME Group stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $109.00, for a total transaction of $32,700.00. Following the completion of the transaction, the director now directly owns 42,802 shares of the company’s stock, valued at $4,665,418. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by insiders.
About CME Group
CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME).
Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.